Sunitinib

Recent Results in Cancer Research

Volumn 184, Issue , 2010, Pages 71-82

  Heng, Daniel Y C ^a   Kollmannsberger, Christian ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; APREPITANT; BEVACIZUMAB; CAPECITABINE; CYTOCHROME P450 3A4; DILTIAZEM; DIPHENOXYLATE; DOCETAXEL; DRUG METABOLITE; ERLOTINIB; FLUOROURACIL; FLUOXETINE; FOLINIC ACID; HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR ALPHA; INTERLEUKIN 2; KETOCONAZOLE; LOPERAMIDE; OXALIPLATIN; PACLITAXEL; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; SORAFENIB; STEM CELL FACTOR; SU 012662; SUNITINIB; THYROTROPIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR; VON HIPPEL LINDAU PROTEIN;

ADVANCED CANCER; ANGIOGENESIS; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ASTHENIA; BLADDER CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CARDIOTOXICITY; CLEAR CELL CARCINOMA; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; EVENING DOSAGE; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; GENOTYPE; GRAPEFRUIT JUICE; HAIR DISEASE; HAND FOOT SYNDROME; HEART LEFT VENTRICLE FAILURE; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; IC 50; KIDNEY CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; METASTASIS; MORNING DOSAGE; MUCOSA INFLAMMATION; OVARY CANCER; OVERALL SURVIVAL; PERITONEUM CANCER; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; RECURRENT CANCER; REVIEW; SIGNAL TRANSDUCTION; SKIN MANIFESTATION; SOLID TUMOR; STOMATITIS; TESTIS CANCER; THROMBOCYTOPENIA; THYROTROPIN BLOOD LEVEL; TREATMENT RESPONSE; UTERINE TUBE CARCINOMA; VON HIPPEL LINDAU DISEASE;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CLINICAL TRIALS AS TOPIC; DRUG INTERACTIONS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; INDOLES; KIDNEY NEOPLASMS; NEOPLASMS; PYRROLES;

EID: 77950526804     PISSN: 00800015     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-01222-8_6     Document Type: Review

References (62)

1. Banks RE, Tirukonda P, Taylor C et al (2006) Genetic and epigenetic analysis of von hippel-lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. Cancer Res 66:2000-2011
2. Biagi JJ, Oza AM, Grimshaw R et al (2008) A phase II study of sunitinib (SU11248) in patients (pts) with recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma - NCIC CTG IND 185. J Clin Oncol 26:5522
3. Blanke CD, Rankin C, Demetri GD et al (2008) Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 26:626-632
4. Brahmer JR, Govindan R, Novello S et al (2007) Efficacy and safety of continuous daily sunitinib dosing in previously treated advanced non-small cell lung cancer (NSCLC): results from a phase II study. J Clin Oncol 25:7542
5. Brauch H, Weirich G, Brieger J et al (2000) VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation. Cancer Res 60: 1942-1948
6. Bukowski RM, Kabbinavar FF, Figlin RA et al (2007) Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol 25:4536-4541
7. Burstein HJ, Elias AD, Rugo HS et al (2008) Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 26: 1810-1816
8. Coppin C, Le L, Porzsolt F, et al (2008) Targeted therapy for advanced renal cell carcinoma. Cochrane Database Syst Rev (2):CD006017
9. Coppin C, Porzsolt F, Awa A, et al (2005) Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev (1):CD001425
10. Choueiri TK, Plantade A, Elson P et al (2008) Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 26:127-131
11. Chow LQ, Eckhardt SG (2007) Sunitinib: from rational design to clinical efficacy. J Clin Oncol 25:884-896
12. Christensen JG (2007) A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities. Ann Oncol 18(Suppl 10):x3-x10
13. Clifford SC, Prowse AH, Affara NA et al (1998) Inactivation of the von hippel-lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: Evidence for a VHL-independent pathway in clear cell renal tumourigenesis. Genes Chromosomes Cancer 22:200-209
14. Cohen HT, McGovern FJ (2005) Renal-cell carcinoma. N Engl J Med 353:2477-2490
15. Cooney MM, Garcia J, Brell J et al (2007) A phase I study of bevacizumab in combination with sunitinib in advanced solid tumors. J Clin Oncol 25:15532
16. Corless CL, Fletcher JA, Heinrich MC (2004) Biology of gastrointestinal stromal tumors. J Clin Oncol 22:3813-3825
17. Dematteo RP, Gold JS, Saran L et al (2008) Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer 112: 608-615
18. Demetri GD, van Oosterom AT, Garrett CR et al (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368:1329-1338
19. Demetri GD, von Mehren M, Blanke CD et al (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472-480
20. Faivre S, Delbaldo C, Vera K et al (2006) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24:25-35
21. Feldman DR, Kondagunta GV, Ronnen EA et al (2007) Phase I trial of bevacizumab plus sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol 25:5099
22. Figlin RA, Hutson TE, Tomczak P et al (2008) Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC). J Clin Oncol 26: 5024
23. Foster K, Prowse A, van den Berg A et al (1994) Somatic mutations of the von hippel-lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma. Hum Mol Genet 3: 2169-2173
24. George S, Blay JY, Casali PG et al (2008) Continuous daily dosing (CDD) of sunitinib (SU) in pts with advanced GIST: updated efficacy, safety, PK and pharmacodynamic analysis. J Clin Oncol 26: 10554
25. Gnarra JR, Tory K, Weng Y et al (1994) Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 7:85-90
26. Goodman VL, Rock EP, Dagher R et al (2007) Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res 13:1367-1373 (Pubitemid 46450424)
27. Gore ME, Porta C, Oudard S et al (2007) Sunitinib in metastatic renal cell carcinoma (mRCC): preliminary assessment of toxicity in an expanded access trial with subpopulation analysis. J Clin Oncol 25:5010
28. Heinrich MC, Corless CL, Demetri GD et al (2003) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21:4342-4349
29. Heinrich MC, Maki RG, Corless CL et al (2008) Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol 26:5352-5359
30. Heng DY, Bukowski RM (2007) Renal cell carcinoma: Evolving approaches to advanced nonclear cell carcinoma. Oncol Rev 1:170-176
31. Heng DY, Chi KN, Murray N et al (2009) A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer. Cancer 115:776-783
32. Houk BE, Bello CL, Michaelson MD et al (2007) Exposure-response of sunitinib in metastatic renal cell carcinoma (mRCC): a population pharmacokinetic/ pharmacodynamic (PKPD) approach. J Clin Oncol 25:5027
33. Houk B, Garrett M, Bello C (2005) Population pharmacokinetics of SU011248 and its primary metabolite SU12662 in oncology patients and healthy volunteers. Presented at the EORTC/ AACR/NCI Molecular Targets Meeting. Philadelphia, PA, November 14-18
34. Jemal A, Siegel R, Ward E et al (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71-96
35. Kenck C, Wilhelm M, Bugert P et al (1996) Mutation of the VHL gene is associated exclusively with the development of non-papillary renal cell carcinomas. J Pathol 179:157-161
36. Kollmannsberger C, Heng DY, Murray N et al (2007a) A population-based study evaluating metastatic renal cell cancer (mRCC) patients treated with interferon (IFN) alone, first-line IFN then second-line sunitinib, or sunitinib alone. J Clin Oncol 25:15572
37. Kollmannsberger C, Soulieres D, Wong R et al (2007b) Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects. Can Urol Assoc J 1:S41-S54
38. Kondo K, Yao M, Yoshida M et al (2002) Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters. Genes Chromosomes Cancer 34:58-68
39. Kovacs G, Akhtar M, Beckwith BJ et al (1997) The heidelberg classification of renal cell tumours. J Pathol 183:131-133
40. Laird AD, Vajkoczy P, Shawver LK et al (2000) SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res 60:4152-4160
41. Maki RG, Fletcher JA, Heinrich MC et al (2005) Results from a continuation trial of SU11248 in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumor (GIST). J Clin Oncol 23:9011
42. McDermott DF, Regan MM, Clark JI et al (2005) Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 23:133-141
43. Mendel DB, Laird AD, Xin X et al (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/ pharmacodynamic relationship. Clin Cancer Res 9:327-337
44. Motzer RJ, Bacik J, Murphy BA et al (2002) Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20: 289-296
45. Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124 (Pubitemid 46089672)
46. Motzer RJ, Michaelson MD, Redman BG et al (2006a) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24:16 -24
47. Motzer RJ, Rini BI, Bukowski RM et al (2006b) Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295:2516-2524
48. Negrier S, Escudier B, Lasset C et al (1998) Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe francais d'immunotherapie. N Engl J Med 338: 1272-1278
49. Negrier S, Perol D, Ravaud A et al (2007) Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial. Cancer 110:2468-2477
50. Nowain A, Bhakta H, Pais S et al (2005) Gastrointestinal stromal tumors: clinical profile, pathogenesis, treatment strategies and prognosis. J Gastroenterol Hepatol 20:818-824
51. Rini BI, Choueiri TK, Elson P et al (2008) Sunitinib-induced macrocytosis in patients with metastatic renal cell carcinoma. Cancer 113: 1309-1314
52. Rini BI, Small EJ (2005) Biology and clinical development of vascular endothelial growth factortargeted therapy in renal cell carcinoma. J Clin Oncol 23:1028-1043
53. Rini BI, Tamaskar I, Shaheen P et al (2007) Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 99:81-83
54. Shuin T, Kondo K, Torigoe S et al (1994) Frequent somatic mutations and loss of heterozygosity of the von hippel-lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res 54:2852-2855
55. Sun L, Liang C, Shirazian S et al (2003) Discovery of 5-[5-fluoro-2-oxo-1, 2- dihydroindol-(3Z)-ylidenemethyl]-2, 4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J Med Chem 46: 1116-1119 (Pubitemid 36428215)
56. Van Glabbeke M, Verweij J, Casali PG et al (2005) Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. J Clin Oncol 23:5795-5804
57. Verweij J, Casali PG, Zalcberg J et al (2004) Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364:1127-1134
58. Weisberg E, Griffin JD (2003) Resistance to imatinib (glivec): update on clinical mechanisms. Drug Resist Updat 6:231-238
59. Witteles RM, Telli ML, Fisher GA et al (2008) Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. J Clin Oncol 26: 9597
60. Wolter P, Stefan C, Decallonne B et al (2008) The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation. Br J Cancer 99:448-454
61. Wong E, Rosen LS, Mulay M et al (2007) Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid 17:351-355
62. Yang JC, Sherry RM, Steinberg SM et al (2003) Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 21:3127-3132